Article

Ixekizumab, With Or Without Concomitant Methotrexate, Improves Signs And Symptoms Of Psa: Week 52 Results From Spirit-P1 And Spirit-P2 Studies

2020-11-17

Abstract excerpt

<title>Abstract</title> <p><bold>Background: </bold>The efficacy and safety of ixekizumab (IXE) with and without continuous concomitant methotrexate (MTX), for up to 52 weeks of treatment, was evaluated in patients with active psoriatic arthritis (PsA). <bold>Methods: </bold>Patients with active PsA who were biologic-naive (SPIRIT-P1) or had prior inadequate response to tumor necrosis factor inhibitors (SPIRIT-P2...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: bc9921fe-d8ce-5093-8272-f2aa1de9256a
DOI: 10.21203/rs.3.rs-46999/v2

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Ixekizumab, With Or Without Concomitant Methotrexate, Improves Signs And Symptoms Of Psa: Week 52 Results From Spirit-P1 And Spirit-P2 StudiesDOI 10.21203/rs.3.rs-46999/v2Read

Efficacy of Risankizumab across distinct PsA phenotypes identified with machine learning analytics using data from biologic DMARD-Naïve patients in two phase 3 clinical trials.Semantic proximity Read

Phenotypic differences and treatment persistence in a large multicentre cohort of axial psoriatic arthritis.Semantic proximity Read

Systemic Treatment Strategies for Patients with Psoriasis and Psoriatic Arthritis in the Setting of ANA Positivity or Lupus Spectrum Disease: A Comprehensive Systematic ReviewSemantic proximity Read

Risankizumab: Mechanism of action, clinical and translational scienceSemantic proximity Read

Telitacicept: A novel horizon in targeting autoimmunity and rheumatic diseasesSemantic proximity Read

Effectiveness and safety of biological and target synthetic drugs treatment for psoriatic arthritis: a systematic review with network meta-analysisSemantic proximity Read

Using ultrasound to define inflammatory and non-inflammatory phenotypes in difficult-to-treat psoriatic arthritis.Semantic proximity Read

Efficacy and Safety of Guselkumab and Adalimumab for Pustulotic Arthro-Osteitis and their Impact on Peripheral Blood ImmunophenotypesSemantic proximity Read

Psoriatic arthritis: a review.Semantic proximity Read

Modern Pharmacologic Management of Rheumatoid Arthritis: From Methotrexate to Targeted TherapiesSemantic proximity Read

The Role of Tumor Necrosis Factor-α Blockers in Psoriatic Disease. Therapeutic Options in Psoriatic Arthritis.Semantic proximity Read

Safety, Pharmacokinetics, Biomarker Response, and Efficacy of E6742, a Dual Antagonist of Toll-Like Receptors 7 and 8, in a First-in-Patient, Randomized, Double-Blind, Phase 1/2 Study in Systemic Lupus ErythematosusSemantic proximity Read